氨甲蝶呤联合英夫利西单抗的效果不优于英夫利西单抗单药治疗克罗恩病
BACKGROUND & AIMS: Methotrexate and infliximab are effective therapies for Crohn's disease (CD). In the combination of maintenance methotrexate-infliximab trial, we evaluated the potential superiority of combination therapy over infliximab alone.
METHODS: In a 50-week double-blind, placebo-controlled trial, we compared methotrexate and infliximab to infliximab alone in 126 patients with CD who had initiated prednisone induction therapy (15 to 40 mg/day) within the preceding 6 weeks. Patients were randomly assigned to groups given methotrexate at an initial weekly dose of 10 mg, escalating to 25 mg/week (n=63), or placebo (n=63) . Both groups received infliximab (5 mg/kg of body weight) at weeks 1, 3, 7, 14 and every 8 weeks thereafter. Prednisone was tapered, beginning at week 1, and discontinued no later than week 14. The primary outcome was time to treatment failure, defined as lack of prednisone-free remission (CD Activity Index <150) at week 14 or failure to maintain remission through week 50.
RESULTS: Patients' baseline characteristics were similar between groups. By week 50, the actuarial rate of treatment failure was 30.6% in the combination therapy group compared with 29.8% in the infliximab monotherapy group (P = .63; hazard ratio, 1.16; 95% confidence interval, 0.62-2.17). Pre-specified subgroup analyses failed to show a benefit in patients with short disease duration or an increased level of C-reactive protein. No clinically meaningful differences were observed in secondary outcomes. Combination therapy was well tolerated.
CONCLUSIONS: The combination of infliximab and methotrexate, although safe, was no more effective than infliximab alone in patients with CD receiving treatment with prednisone.
- 您可能感兴趣的文章
-